Stock Research for CTIC


Featured Broker: Ally Invest

Get the due diligence for another stock.


CTIC Stock Chart & Research Data

The CTIC chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CTIC chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


CTIC Due diligence Resources & Stock Charts

The CTIC stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CTIC Detailed Price Forecast - CNN Money CNN View CTIC Detailed Summary - Google Finance
Yahoo View CTIC Detailed Summary - Yahoo! Finance Zacks View CTIC Stock Research & Analysis -

Stock Analysis

TradeIdeas View CTIC Trends & Analysis - Trade-Ideas Barrons View CTIC Major Holders - Barrons
NASDAQ View CTIC Call Transcripts - NASDAQ Seeking View CTIC Breaking News & Analysis - Seeking Alpha
Spotlight View CTIC Annual Report - OTC Report View CTIC OTC Short Report -
TradeKing View CTIC Fundamentals - TradeKing Charts View CTIC SEC Filings - Bar Chart
WSJ View Historical Prices for CTIC - The WSJ Morningstar View Performance/Total Return for CTIC - Morningstar
MarketWatch View the Analyst Estimates for CTIC - MarketWatch CNBC View the Earnings History for CTIC - CNBC
StockMarketWatch View the CTIC Earnings - StockMarketWatch MacroAxis View CTIC Buy or Sell Recommendations - MacroAxis
Bullish View the CTIC Bullish Patterns - American Bulls Short Pains View CTIC Short Pain Metrics -

Social Media Mentions

StockTwits View CTIC Stock Mentions - StockTwits PennyStocks View CTIC Stock Mentions - PennyStockTweets
Twitter View CTIC Stock Mentions - Twitter Invest Hub View CTIC Investment Forum News - Investor Hub
Yahoo View CTIC Stock Mentions - Yahoo! Message Board Seeking Alpha View CTIC Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for CTIC - Insider Cow View Insider Transactions for CTIC - Insider Cow
CNBC View CTIC Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CTIC - OTC Markets
Yahoo View Insider Transactions for CTIC - Yahoo! Finance NASDAQ View Institutional Holdings for CTIC - NASDAQ

Stock Charts

FinViz View CTIC Stock Insight & Charts - StockCharts View CTIC Investment Charts -
BarChart View CTIC Stock Overview & Charts - BarChart Trading View View CTIC User Generated Charts - Trading View

Latest Financial News for CTIC

What Should You Know About CTI BioPharma Corp’s (NASDAQ:CTIC) Earnings Trajectory?
Posted on Wednesday April 18, 2018

The latest earnings announcement CTI BioPharma Corp’s (NASDAQ:CTIC) released in December 2017 confirmed company earnings became less negative compared to the previous year’s level as a result of recent tailwindsRead More...

Wired News – CTI BioPharma’s Pacritinib Phase-3 PERSIST-2 Clinical Trial Data Published in JAMA Oncology
Posted on Tuesday March 13, 2018

Stock Monitor: Fate Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 13, 2018 / has just released a free research report on CTI BioPharma Corp. (NASDAQ: CTIC ). ...

CTI BioPharma to Present at Upcoming Investor Conferences
Posted on Friday March 09, 2018

SEATTLE , March 9, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present and host one-on-one meetings at the following investor conferences ...

CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
Posted on Friday March 09, 2018

SEATTLE, March 9, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (CTIC) today announced that results from the Phase 3 PERSIST-2 clinical trial of pacritinib (an investigational JAK2 inhibitor) have been published online in JAMA Oncology. The randomized, international, multicenter study compared the efficacy and safety of pacritinib at two dose levels, compared with best available therapy (BAT), which included ruxolitinib (a JAK1/JAK2 inhibitor), in patients with myelofibrosis and thrombocytopenia (defined as platelet counts ≤100 x 109/L). In the intent-to-treat patient population of the study, the combined pacritinib arms (400mg once daily and 200mg twice daily dosing, 149 patients total) demonstrated a significant improvement of 35% or more in spleen volume reduction (SVR) at 24 weeks of treatment in 27 patients (18%) compared to 2 patients (3%) out of 72 patients in the BAT arm, which included treatment with ruxolitinib (P=0.001).

Enter a stock symbol to view the stock details.